[Clinical study of the month. Secondary prevention of cerebrovascular accident with perindopril: the PROGRESS study].
PROGRESS ("Perindopril pROtection aGainst REcurrent Stroke Study") demonstrated that blood-pressure lowering treatment with perindopril, an angiotensin converting enzyme inhibitor (combined with the diuretic agent indapamide when necessary), reduces the risk of stroke by 28% (95% CI: 17-38, p < 0.0001) among patients with a history of stroke or transient ischaemic attack. This protective effect was observed among both hypertensive and non-hypertensive individuals. It was more marked in the patients receiving combined perindopril + indapamide treatment (-43%; 95% CI 30-54) who were those who showed the greatest reduction in arterial blood pressure (-12/5 mm Hg). According to these observations, the authors concluded that treatment with these two agents should now be considered routinely for patients with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.
Scheen
A J
AJ
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications*; D007190:Indapamide / Q000494:pharmacology* / Q000627:therapeutic use; D007391:International Cooperation; D015337:Multicenter Studies as Topic; D020913:Perindopril / Q000494:pharmacology* / Q000627:therapeutic use; D011315:Preventive Medicine; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D007190:Indapamide; D020913:Perindopril